Informa Markets in India has recently hosted the 17th edition of CPHI & PMEC India at the India Expo Centre, Greater Noida, Delhi-NCR, showcasing the robust potential of India’s pharmaceutical industry.

With the Indian pharma market projected to grow to USD 130 billion by 2030 and USD 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Bringing together over 2,000 exhibitors and 50,000 visitors from more than 150 countries, including the USA, UAE, South Korea, Japan, and the United Kingdom, the expo serves as a dynamic hub for innovation and collaboration.

Spanning pharma machinery, packaging, analytical instruments, laboratory technologies, ingredients, and beyond, it offers a comprehensive platform for stakeholders to engage in transformative dialogues and foster strategic partnerships.

The grand inauguration of the 17th edition of CPHI &PMEC India, took place, setting the tone for a spectacular showcase of the pharmaceutical and healthcare industries' future. Key dignitaries such as K. Raja Bhanu, Director General, Pharmexcil; Harish K. Jain, President, FOPE (Federation of Pharma Entrepreneurs) ; Namit Joshi, Vice Chairman, Pharmexcil; Mr. AVPS Chakravarthy, Global Ambassador, WPO; Rhonda Duffy, Executive Vice President and COO, Biocon Biologics;  Rakesh Kumar, Chairman, India Expo Mart Limited (IEML) & Director General, Export Promotion Council for Handicrafts (EPCH); Mr R.K. Jain, Chairman, CPI; Ranjana Ganguly, Board Member, PCSI; Yogesh Mudras, Managing Director, Informa Markets in India, Wouter Moulman, Chief Commercial Officer, Informa Markets, IMEA, Adam Anderson, Executive Vice President - Pharma, Informa Markets B.V.;  and Rahul Deshpande, Sr. Group Director, Informa Markets in India, did the honours, amidst an august industry presence.

The event featured a stellar lineup of exhibitors, including leading names like Dr. Reddy's Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, Apitoria Pharma Pvt Ltd, Capsugel Healthcare Pvt. Ltd, Supriya Lifescience Ltd, SMS Pharmaceuticals Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, and Merck Life Science Pvt. Ltd, among others. The PMEC pavilion showcases cutting-edge pharmaceutical manufacturing technologies, with prominent exhibitors like ACG, Accupack Engineering, Ace Technologies, Avish Machines, Bowman & Archer Pharma Machines, Cadmach Machinery, CAM PAK India, Fette India, IMA Industria Macchine, Parle Global Technologies, Snowbell Machines, and Truking Technology, spotlighting the latest advancements in equipment and innovation.

This year, the expo garnered strong support from prominent industry associations, including CIPI, FOPE (Federation of Pharma Entrepreneurs), IPEC India, and Pharmexcil, further cementing its status as a leading and highly anticipated event in the pharmaceutical industry.

AVPS Chakravarthy, Global Ambassador, WPO, said, "The Indian pharmaceutical industry is demnstrating its innovative potential through advancements like Carticel therapy for cancer treatment and Nafithromycin, a groundbreaking macrolide antibiotic tackling drug-resistant pathogens. These innovations highlight India's dual strengths in affordability and efficacy, reaffirming its role as the 'pharmacy of the world.' Events like CPHI & PMEC India provide vital platforms for collaboration, showcasing progress in AI-driven drug inspection, sustainable packaging, and startup-driven innovations, propelling the industry towards a future of higher value creation and global leadership in both volume and value."

Dr. Veeramani, Chairman, Pharmexcil, said, “The Indian pharmaceutical industry stands as a global leader, exporting to over 200 countries and providing comprehensive solutions across APIs, finished dosages, clinical research, and pharmacovigilance. With platforms like CPHI showcasing India's capabilities, the sector is poised for transformative growth—from its current $55 billion to a projected $130 billion by 2030 and $450 billion by 2047. Innovations in biologics, specialty generics, and the impact of policies like the U.S. Biosecure Act underline the industry's potential to redefine healthcare solutions worldwide.”

K. Raja Bhanu, Director General, Pharmexcil, said, “The Indian pharmaceutical sector, a key focus area for exports, has demonstrated remarkable growth, with current market size at $55 billion and exports contributing USD 27.85 billion. Projections indicate exports will soar to USD 130 billion by 2030 and USD 450 billion by 2047. CPHI & PMEC India highlights India’s strengths in manufacturing, analytics, AI, and machine learning.”

Namit Joshi, Vice Chairman, Pharmexil, said, "The Indian pharmaceutical industry has solidified its global position as the 'Pharmacy of the World' and earned recognition as the 'Healers of the World' through its exceptional contribution to COVID-19 vaccine distribution. With exports nearing $27.84 billion and innovative advancements like nanoparticles and improved drug delivery systems, India continues to lead. Integrating IT with pharmaceuticals will further strengthen its role, paving the way for dominance in biologics and biosimilars. CPHI & PMEC India is instrumental in showcasing this progress and reinforcing India's potential to serve global healthcare needs.”

Harish K. Jain, President, FOPE (Federation of Pharma Entrepreneurs), said, “India's pharmaceutical industry, valued at USD 60 billion, plays a vital role in global exports, with USD 30 billion of that in exports. By 2030, we expect our exports to grow significantly, with 70 percent directed to Europe and the US. Our industry’s impact is enormous—Indian pharmaceuticals contribute $8 billion annually to the US healthcare system, saving patients over USD 1.5 trillion. With growing capabilities in AI, machine learning, and biologics, India is poised to become the world's leading pharmaceutical hub, targeting a USD 1 trillion industry by 2047."

Highlighting the significance of this year’s CPHI & PMEC India Expo, Yogesh Mudras, Managing Director, Informa Markets in India, said, “The Indian pharmaceutical industry stands as a pillar of manufacturing excellence, scale, and research-led competitiveness. Having evolved into a vibrant sector, it now ranks 3rd globally in pharmaceutical production by volume and 14th by value, contributing approximately 1.72% to the nation’s GDP. India is among the top 12 global biotechnology destinations and the third largest in the Asia-Pacific region. This leadership stems from key advantages such as a low manufacturing cost, which is 30 percent-35 percent lower than in the US and Europe, cost-efficient R&D at 87% less than developed markets, and an abundant pool of skilled labor. These strengths position India as a formidable player in shaping the future of global healthcare. The CPHI & PMEC India expo acts as a catalyst in propelling the pharmaceutical industry’s progress, fostering transformative innovations, strategic collaborations, and impactful global synergies. We are also proud to have a Start Up Pavilion under the aegis of the expo, which showcases emerging pharma disruptors with cutting-edge solutions that challenge traditional approaches. This offers attendees a glimpse into the future of the industry.”

Adam Anderson, Executive Vice President - Pharma, Informa Markets B.V, said, “India’s pharmaceutical sector is stronger than ever, not only in raw ingredients but also in machinery and biopharmaceuticals. By 2027, biopharma is projected to account for 35% of the global market, positioning India as a leader. This growth extends across the entire supply chain, including contract manufacturing and packaging, providing India with tremendous opportunities as the industry continues to evolve. CPHI & PMEC India plays a crucial role in showcasing this transformation, bringing together key industry players and fostering innovation.”

Day 1 of the event showcased the Pharma Connect Congress, which addressed pivotal themes shaping the pharmaceutical landscape. Sessions included discussions on continuous innovation and agile manufacturing for next-generation therapeutics, moderated by Dr. Mahesh Bhalgat, Group CEO & MD, Veeda Clinical Research Limited, and insights into India’s position as the “Pharmacy of the World” with cost-effective generics and biosimilars, led by Dr. Rhonda Duffy, Executive Vice-President & Chief Operating Officer, Biocon Biologics.

Additionally, Day 1 featured the Pharma Leaders Roundtable, a closed-door session for senior leaders to explore transformative trends and challenges. Discussions highlighted leveraging geopolitical shifts, such as the BIOSECURE Act, to enhance India’s CDMO sector, integrating AI and machine learning for efficiency, and addressing regulatory and infrastructure barriers in advanced therapies.

The day concluded with the prestigious India Pharma Awards 2024, celebrated outstanding achievements in innovation and excellence within the pharmaceutical industry. This prestigious event highlighted transformative contributions across categories such as R&D, sustainability, and digital innovation, while recognizing individuals with a Lifetime Achievement Award.